Albireo to Present at Investor Conferences in April
April 01 2019 - 7:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will present at
the following investor conferences in April:
H.C. Wainwright & Co. Global Life
Sciences ConferenceLocation: LondonPresentation date /
time: Monday, April 8, 3:10 p.m. BST / 10:10 a.m. EDTPresenter: Ron
Cooper, President and Chief Executive Officer
18th Annual Needham & Company
Healthcare ConferenceLocation: New York CityPresentation
date / time: Wednesday, April 10, 9:20 a.m. EDTPresenter: Simon
Harford, Chief Financial Officer
A live audio webcast of each presentation will be
accessible from the Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15
minutes prior to the scheduled start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following the event.
About Albireo Albireo
Pharma is a clinical-stage biopharmaceutical company focused
through its operating subsidiary on the development of novel bile
acid modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, A4250, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in its initial target indication, progressive familial intrahepatic
cholestasis. Albireo’s clinical pipeline also includes two Phase 2
product candidates. Albireo’s elobixibat, approved
in Japan for the treatment of chronic constipation, is
the first ileal bile acid transporter (IBAT) inhibitor
approved anywhere in the world. Albireo was spun out
from AstraZeneca in 2008.
Albireo Pharma is located
in Boston, Massachusetts, and its key operating
subsidiary is located in Gothenburg, Sweden. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum,
LifeSci Advisors, LLC, 212-915-2568Media Contact:
Heather Anderson, 6 Degrees, 980-938-0260,
handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024